{"schema_version":"secwatch.filing_event.v1","accession":"0001439222-23-000063","form_type":"8-K","ticker":"AGIO","cik":"0001439222","company_name":"AGIOS PHARMACEUTICALS, INC.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.880386+00:00","generated_at":"2026-06-15T21:34:39.769346+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Agios Q1 2023: PYRUKYND revenue $5.6M, net loss improves to $81M, cash $1.0B","bullets":["PYRUKYND net revenue of $5.6M in Q1 2023; 127 unique patients enrolled, 89 on therapy.","Net loss of $81.0M improved from $94.8M in Q1 2022; R&D expense $67.3M, SG&A $28.4M.","Cash, cash equivalents and marketable securities $1.0B as of March 31, 2023.","Phase 2 sickle cell data (RISE UP) expected mid-2023; ENERGIZE/ENERGIZE-T enrollment closed.","Appointed Jeffrey Capello to board; Paul Clancy stepping down effective June 13, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001439222-23-000063","json":"https://secwatch.observer/filing/0001439222-23-000063.json","markdown":"https://secwatch.observer/filing/0001439222-23-000063.md","text":"https://secwatch.observer/filing/0001439222-23-000063.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000063/0001439222-23-000063-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000063/agio-20230504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T21:34:39.769346+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6e1b603de24768990e1fd17e40221a6ae0e62ca7","claim":"AGIOS PHARMACEUTICALS, INC. reported the first quarter ended March 31, 2023 results: revenue $5.6 million, net income $81.0 million.","evidence_excerpt":"Phase 2 Portion of the RISE UP Study in Sickle Cell Disease in Mid-2023 and the Phase 3 ENERGIZE and ENERGIZE-T Studies in Thalassemia in 2024 • U.S. PYRUKYND ® Net Revenue of $5.6 Million in Q1; $1.0 Billion of Cash, Cash Equivalents and Marketable Securities as of March 31, 2023 CAMBRIDGE, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000063/0001439222-23-000063-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"$5.6 million"},{"label":"Net income","value":"$81.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}